Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2017-2022: Potential ofIinsulin Biosimilars like Basaglar is Huge in the Upcoming Future - Research and Markets

DUBLIN, Mar 03, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022" report to their offering.

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022 report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market.

This report analyzes various aspects like rationale design of insulin molecule, mechanism of  insulin in diabetes, engineering of synthetic insulin,  global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of biosimilar insulin market.

The consequence of recent technological innovations, new regulations in the biopharmaceutical industry, and cost concerns, the idea of biosimilars has gathered attention towards them and their potential future market. In fact, efforts are already underway to develop a new class of follow-on biologics named biobetters or biosuperiors, which go beyond mimicking the original biologic to provide improvements through changes in chemistry, alteration in the formulation, and innovative delivery.

The potential of insulin biosimilars like Basaglar is huge in the upcoming future, the demand will significantly grow in developed market as the countries including US, Europe and Japan have shown a great enthusiasm towards biosimilar products especially Europe. The developed market somehow, with the exception of the United States, has represented the greatest biosimilars presence today. Most biosimilars manufacturers have been and remain focused on the developed markets whether it is for their historic and current opportunities (EU) or for their future market potential (United States, Japan).

Key Topics Covered:

1. Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution & Development

2. Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin

3. Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact of Insulin Resistance in Diabetes 2

4. Engineering of Synthetic Insulin
4.1 Production of Human Insulin
4.2 Categorization of Insulin & Its Analogues
4.2.1 Rapid Acting Insulins
4.2.2 Short Acting Insulins
4.2.3 Intermediate Insulin
4.2.4 Long Lasting Insulins

5. Insulinotherapeutics in Diabetes
5.1 Conventional Insulinotherapy
5.2 Flexible or Intensive Insulinotherapy

6. Global Economic Aspects of Insulin
6.1 Skyrocketing Cost of Insulin Therapies
6.2 Emergence of Biosimilar

7. Global Economic Cost of Diabetes
7.1 Monetary Burden of Diabetes
7.2 US
7.3 Europe
7.4 Japan
7.5 China
7.6 India

8. Global Aspects of Biosimilar Insulins
8.1 US
8.2 Europe
8.3 Japan
8.4 Asia (Excluding Japan)

9. Global Biosimilar Insulin Market Overview
9.1 Preface to Biosimilar Insulin Market
9.2 Biosimilar Competition Assessment

10. Global Biosimilar Insulin Clinical Pipeline Insight

11. Marketed Biosimilar Insulin Clinical Insight by Company, Indication & Phase
11.1 Insulin Biosimilar (Wosulin-R)
11.2 Insulin Glargine Biosimilar (Glaritus, Glaritus Cart, Glaritus DispoPen)
11.3 Insulin Glargine Biosimilar (Abasaglar, Abasria & Basalgar)
11.4 Insulin Suspension Isophane/Insulin Biosimilar (Jusline 30/70)
11.5 Insulin Glargine Biosimilar (Basalog & GALACTUS)
11.6 Insulin Suspension Isophane Biosimilar (Jusline N)
11.7 Insulin Suspension Isophane/Insulin Biosimilar (Insulin H Mix)
11.8 Insulin Suspension Isophane Biosimilar (Insulin Hbio NPH)
11.9 Insulin Biosimilar (Insulin Hbio R)
11.10 Insulin Glargine Biosimilar (Basalin)
11.11 Insulin/Insulin Suspension Isophane Biosimilar (Wosulin 30/70, 50/50)
11.12 Insulin Suspension Isophane Biosimilar (Wosulin-N)
11.13 Insulin Biosimilar (Jusline R)
11.14 Insulin Glargine Biosimilar (Basugine)
11.15 Insulin Biosimilar (Insugen)

12. Biosimilar Insulin Future Targeted Market
12.1 Global High Prevalence of Diabetics
12.2 Global Prevalence of Obesity

13. Global Biosimilar Insulin Market Dynamics
13.1 Accelerating Parameters
13.2 Major Challenges of Biosimilar Insulin Market

14. Future Implications of Biosimilar Insulin

15. Competitive Landscape
15.1 Biocon
15.2 Biogenomics
15.3 Eli Lilly
15.4 Gan&Lee Pharmaceuticals
15.5 Geropharm
15.6 Julphar Gulf Pharmaceutical Industries
15.7 Paras Biopharmaceuticals
15.8 Samsung Bioepis
15.9 Sedico
15.10 Wockhardt

For more information about this report visit http://www.researchandmarkets.com/research/m7sg98/global_biosimilar

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716